PUK2 Hospitalization in Patients Receiving Maintenance Dialysis with Hyperphosphatemia Randomized to Tenapanor or Sevelamer

In patients on maintenance dialysis, hyperphosphatemia is a risk factor for mortality and hospitalization. Tenapanor an investigational, first-in-class, phosphate absorption inhibitor, providing novel, non-binder approach to treating hyperphosphatemia. The PHREEDOM study was long-term Phase 3 trial evaluating the safety efficacy of tenapanor treat in dialysis (hemo- or peritoneal dialysis). This post-hoc analysis aims identify effects relative sevelamer hospitalization length stay. 52-week consisting 26-week, open-label, randomized treatment period with 12-week placebo-controlled withdrawal period, followed by 14-week open label extension period. Patients serum phosphorus ≥ 6.0 mg/dL 1.5 increase following binder washout were 3:1 receive one 30 mg tablet twice daily per package insert At end all arm re-randomized 1:1 placebo Sevelamer used as control comparison serious adverse events hospitalizations. Results intention-to-treat principle. proportion who experienced any event leading at 26 weeks 17.4% receiving 23.4% sevelamer; average duration longer sevelamer, compared (9.75 days ± 9.8 vs. 8.86 8.28 days). had lower rates shorter lengths stay when occurred, sevelamer.